Regulatory Post-Marketing Surveillance (PMS) Study for AVAXIM 160U (Hepatitis A Vaccine)
Phase of Trial: Phase IV
Latest Information Update: 29 Jul 2016
Price : $35 *
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary) ; Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Adverse reactions
- Sponsors sanofi pasteur
- 25 Jul 2016 Status changed from active, no longer recruiting to completed.
- 09 Oct 2015 Planned End Date changed from 1 Nov 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
- 09 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.